.png)
The demand for glucagon-like peptide 1 (GLP-1) receptor agonists for overweight/obesity has created a clinical conundrum for many primary care providers. Between 2011 and 2023, obesity-specific prescriptions for GLP-1s increased by 700%. Since then, roughly 1 in 5 Americans have reportedly taken these drugs to lose weight...
55W 14th St Ste 101, Helena, Montana, 59601, US
+1(406)-319-1601
news.in.usa@olahost.top
Copyright © 2024 olascience. All Rights Reserved
